의료용 대규모 언어 모델(LLM) 시장 규모, 점유율 및 동향 분석 보고서 : 구성 요소별, 용도별, 도입 형태별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Large Language Models In Healthcare Market Summary

The global large language models in healthcare market size was estimated at USD 1.3 billion in 2025 and is projected to reach USD 12.5 billion in 2033, growing at a CAGR of 32.3% from 2026 to 2033. Rising volume of unstructured healthcare data, increasing adoption of AI in healthcare IT ecosystems, expansion of use cases in drug discovery and life sciences are factors driving the growth of the global large language models (LLM) in the healthcare market.

The section below outlines the key factors driving the growth of large language models (LLM) in healthcare market, highlighting the Rising volume of unstructured healthcare data, increasing adoption of AI in healthcare IT ecosystems, and expansion of use cases in drug discovery and life sciences.

Global Large Language Models In Healthcare Market Report Segmentation

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global large language models (LLM) in healthcare market report based on component, application, deployment mode, end-use, and region:

• Component Outlook (Revenue, USD Million, 2021 - 2033)
• Software and GPT Platform
• Services
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical Documentation & Ambient AI
• Clinical Decision Support
• Drug Discovery & Life Sciences
• Patient Engagement & Virtual Assistants
• Administrative & Revenue Cycle Mgmt
• Others
• Deployment Mode Outlook (Revenue, USD Million, 2021 - 2033)
• Web & Cloud-based
• On-premise
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Physician Practices & Ambulatory Clinics
• Pharmaceutical & Biotech Companies
• Payer
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Component Segment
  • 1.2.2. Application Segment
  • 1.2.3. Deployment Mode Segment
  • 1.2.4. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Large Language Models (LLM) in Healthcare Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
  • 3.2.3. Market opportunity analysis
  • 3.2.4. Market challenges analysis
• 3.3. Large Language Models (LLM) in Healthcare Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
    • 3.3.2.4. Environmental Landscape
    • 3.3.2.5. Legal Landscape
    • 3.3.2.6. Social Landscape

Chapter 4. Large Language Models (LLM) in Healthcare Market: Component Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Large Language Models (LLM) in Healthcare Market Component Movement Analysis
• 4.3. Global Large Language Models (LLM) in Healthcare Market Size & Trend Analysis, by Component, 2021 to 2033 (USD Million)
• 4.4. Software and GPT Platform
  • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Services
  • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Large Language Models (LLM) in Healthcare Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Large Language Models (LLM) in Healthcare Market Application Movement Analysis
• 5.3. Global Large Language Models (LLM) in Healthcare Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Clinical Documentation & Ambient AI
  • 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Clinical Decision Support
  • 5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Drug Discovery & Life Sciences
  • 5.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Administrative & Revenue Cycle Management
  • 5.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.8. Patient Engagement & Virtual Assistants
  • 5.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Large Language Models (LLM) in Healthcare Market: Deployment Mode Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Large Language Models (LLM) in Healthcare Market: Deployment Mode Movement Analysis
• 6.3. Global Large Language Models (LLM) in Healthcare Market Size & Trend Analysis, by Medical Condition, 2021 to 2033 (USD Million)
• 6.4. Web & Cloud-based
  • 6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. On-Premise
  • 6.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Large Language Models (LLM) in Healthcare Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Large Language Models (LLM) in Healthcare Market: End Use Movement Analysis
• 7.3. Global Large Language Models (LLM) in Healthcare Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.4. Hospitals
  • 7.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Physician Practices & Ambulatory Clinics
  • 7.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Pharmaceutical & Biotechnology Companies
  • 7.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Payers
  • 7.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. Others
  • 7.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Large Language Models (LLM) in Healthcare Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 8.4. North America
  • 8.4.1. U.S.
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.2. Canada
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.3. Mexico
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. UK
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. Germany
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. France
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.4. Italy
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.5. Spain
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.6. Norway
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.7. Sweden
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.8. Denmark
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Regulatory framework
    • 8.5.8.3. Competitive scenario
    • 8.5.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Japan
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. India
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.4. Australia
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.6. Thailand
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Brazil
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. Argentina
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.8. MEA
  • 8.8.1. South Africa
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.2. Saudi Arabia
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.3. UAE
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.4. Kuwait
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Regulatory framework
    • 8.8.4.3. Competitive scenario
    • 8.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2025
• 9.4. Company Profiles/Listing
  • 9.4.1. MedGPT
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. OpenAI
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Google DeepMind
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Microsoft
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Oracle
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Certilytics
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. John Snow Labs
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Merative
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Anthropic
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Meta AI
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. Hippocratic AI
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives
  • 9.4.12. Ambience Healthcare
    • 9.4.12.1. Company overview
    • 9.4.12.2. Financial performance
    • 9.4.12.3. Product benchmarking
    • 9.4.12.4. Strategic initiatives
  • 9.4.13. Abridge AI, Inc.
    • 9.4.13.1. Company overview
    • 9.4.13.2. Financial performance
    • 9.4.13.3. Product benchmarking
    • 9.4.13.4. Strategic initiatives
  • 9.4.14. Tempus AI
    • 9.4.14.1. Company overview
    • 9.4.14.2. Financial performance
    • 9.4.14.3. Product benchmarking
    • 9.4.14.4. Strategic initiatives
  • 9.4.15. Aidoc
    • 9.4.15.1. Company overview
    • 9.4.15.2. Financial performance
    • 9.4.15.3. Product benchmarking
    • 9.4.15.4. Strategic initiatives
  • 9.4.16. Viz.ai
    • 9.4.16.1. Company overview
    • 9.4.16.2. Financial performance
    • 9.4.16.3. Product benchmarking
    • 9.4.16.4. Strategic initiatives
  • 9.4.17. Qure.ai
    • 9.4.17.1. Company overview
    • 9.4.17.2. Financial performance
    • 9.4.17.3. Product benchmarking
    • 9.4.17.4. Strategic initiatives
  • 9.4.18. PathAI
    • 9.4.18.1. Company overview
    • 9.4.18.2. Financial performance
    • 9.4.18.3. Product benchmarking
    • 9.4.18.4. Strategic initiatives
  • 9.4.19. Insilico Medicine
    • 9.4.19.1. Company overview
    • 9.4.19.2. Financial performance
    • 9.4.19.3. Product benchmarking
    • 9.4.19.4. Strategic initiatives
  • 9.4.20. Owkin
    • 9.4.20.1. Company overview
    • 9.4.20.2. Financial performance
    • 9.4.20.3. Product benchmarking
    • 9.4.20.4. Strategic initiatives
  • 9.4.21. Benevolent AI
    • 9.4.21.1. Company overview
    • 9.4.21.2. Financial performance
    • 9.4.21.3. Product benchmarking
    • 9.4.21.4. Strategic initiatives